TLSA Stock Forecast & Price Target

Tiziana Life Sciences is attractive because foralumab offers a mechanistically differentiated, intranasal Treg-based strategy that directly targets CNS inflammation without systemic T-cell depletion, and the company has already shown TSPO-PET reductions across SPMS, MSA, and AD along with no serious adverse events in 37 patient-years of exposure. The upcoming INFORM-MS Phase 2a readout in October 2026, in a 48-patient randomized, double-blind, placebo-controlled trial, is the key near-term catalyst, especially given the reported 64% fatigue improvement in early open-label data and 80% qualitative PET improvement in a 10-patient na-SPMS cohort. Its investment case is further strengthened by major unmet need in SPMS and MSA, Fast Track designation for na-SPMS in July 2024, and an expanding pipeline that could validate a broader platform across neurodegenerative disease.

Tiziana Life Sciences is challenged by the scientific and regulatory uncertainty surrounding neurodegenerative drug development, where complex biology, imperfect causal evidence in humans, and the possibility that later-stage patients respond less well all weaken confidence in Foralumab’s commercial potential. As a clinical-stage biopharmaceutical company with no approved products and a limited operating history, it has already incurred significant operating losses and will likely need substantial additional capital, creating dilution and financing risk if market access is constrained. Its outlook is further pressured by the FDA’s apparent preference for larger, well-controlled datasets and by intensifying competition in neuroinflammation, including rapidly advancing NLRP3 inhibitor programs and established anti-IL-6 agents.